AU2020254882A1 - Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders - Google Patents

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders Download PDF

Info

Publication number
AU2020254882A1
AU2020254882A1 AU2020254882A AU2020254882A AU2020254882A1 AU 2020254882 A1 AU2020254882 A1 AU 2020254882A1 AU 2020254882 A AU2020254882 A AU 2020254882A AU 2020254882 A AU2020254882 A AU 2020254882A AU 2020254882 A1 AU2020254882 A1 AU 2020254882A1
Authority
AU
Australia
Prior art keywords
compound
independently selected
substituted
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020254882A
Other languages
English (en)
Inventor
Marielle Gilles Babel
Reginald Christophe Xavier Brys
Oscar MAMMOLITI
Gregory John Robert NEWSOME
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of AU2020254882A1 publication Critical patent/AU2020254882A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020254882A 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders Abandoned AU2020254882A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1904374.4A GB201904374D0 (en) 2019-03-29 2019-03-29 Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
GB1904374.4 2019-03-29
PCT/EP2020/058063 WO2020200899A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
AU2020254882A1 true AU2020254882A1 (en) 2021-11-25

Family

ID=66443107

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020254882A Abandoned AU2020254882A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Country Status (14)

Country Link
US (1) US20220194938A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947377A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022526176A (cg-RX-API-DMAC7.html)
KR (1) KR20210143904A (cg-RX-API-DMAC7.html)
CN (1) CN113677679A (cg-RX-API-DMAC7.html)
AU (1) AU2020254882A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019110A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134735A1 (cg-RX-API-DMAC7.html)
GB (1) GB201904374D0 (cg-RX-API-DMAC7.html)
IL (1) IL286685A (cg-RX-API-DMAC7.html)
MX (1) MX2021011575A (cg-RX-API-DMAC7.html)
PH (1) PH12021552376A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110678UA (cg-RX-API-DMAC7.html)
WO (1) WO2020200899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
CA2992406A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
WO2017207386A1 (de) * 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
KR20210143904A (ko) 2021-11-29
BR112021019110A2 (pt) 2021-11-30
CN113677679A (zh) 2021-11-19
CA3134735A1 (en) 2020-10-08
PH12021552376A1 (en) 2022-09-19
JP2022526176A (ja) 2022-05-23
IL286685A (en) 2021-10-31
MX2021011575A (es) 2021-10-13
US20220194938A1 (en) 2022-06-23
GB201904374D0 (en) 2019-05-15
WO2020200899A1 (en) 2020-10-08
SG11202110678UA (en) 2021-10-28
EP3947377A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
EP3947378B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2020200898A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US12606554B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
US20190152922A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3947377A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3365341B1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
CA3054652A1 (en) Anti-inflammatory compositions comprising irak and jak inhibitors
WO2025068090A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period